Discontinuation of trials created negative sentiment risk.
Investor base cautious of future uncertainty.
Multifaceted stakeholder groups need differentiated messaging.
Our Approach
Transparent IR strategy – Coordinated messaging post-trial updates with clear pivot plan and asset recap.
Value-tiered communication – Produced sector-targeted materials for:
Investors (webcasts, fact sheets)
Scientists (pipeline whitepaper)
Patients (plain‑language Q&A)
Social narrative shift – Shared positive messaging: “New path forward,” “Building on learnings.”
SEO and content optimization – Elevated Bellicum in searches for cell therapy pivots and biotech strategy.
Results
70% investor webinar attendance with high engagement metrics.
Reuters/Financial press coverage on pivot was neutral-to-positive.
Patient Q&A pages saw 4× traffic post-update, with consistent positive tone in comments.
Conclusion
Accelabrand guided Bellicum through a strategic narrative pivot—balancing transparency with optimism to maintain trust across IR, scientific, and patient communities.
